4
Changes in Ownership
Protalix BioTherapeutics, Inc. Filed Acc 0001104659-22-098950
Options or other derivatives
- Sr. VP and CFO acquired 350,000 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Derivatives | |||||||
| Rubin Eyal Sr. VP and CFO | 2022-09-07 | Grant or award · Stock Options (Right to Buy) | +350,000 | 350,000 | D | ||
Loading xslF345X03/tm2225460-7_4seq1.xml…